KC
HZNP

Kryger Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kryger Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,222,616
Closed -$141M – 18
2023
Q3 		$141M Buy
1,222,616
+225,815
+23% +$24.3M 16.33% 2
2023
Q2 		$103M Sell
996,801
-248,197
-20% -$26.2M 10.49% 2
2023
Q1 		$136M Buy
1,244,998
+159,019
+15% +$17.6M 23.73% 1
2022
Q4 		$124M Buy
+1,085,979
New +$90.2M 18.71% 1

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kryger Capital's HZNP Position: Q4 2023 in Review

Kryger Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,222,616 shares — an estimated $141M sold.

Kryger Capital first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $141M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Kryger Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Kryger Capital sold 1,222,616 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $141M.
  • Kryger Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Kryger Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $141M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Kryger Capital's 13F filing for Q4 2023, filed 13 Feb 2024.